Abstract
Multiple Myeloma (MM) is a severe disease characterized by extensive inter-patient heterogeneity, which is also reflected in the patient pathways. Moreover, patient pathways are highly heterogeneous across different jurisdictions. Current health economic models only focus on the economic analysis of a single decision and only vaguely consider the wider context. This research aimed to establish transparency of economic evaluations in health technologies in MM and provide guidance and recommendations for future health economic analyses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
